2023
Stroke reduction by cerebral embolic protection devices in transcatheter aortic valve implantation: a systematic review and Bayesian meta-analysis
Heuts S, Gabrio A, Veenstra L, Maesen B, Kats S, Maessen J, Walton A, Nanayakkara S, Lansky A, van 't Hof A, Vriesendorp P. Stroke reduction by cerebral embolic protection devices in transcatheter aortic valve implantation: a systematic review and Bayesian meta-analysis. Heart 2023, 110: 757-765. PMID: 37996242, DOI: 10.1136/heartjnl-2023-323359.Peer-Reviewed Original ResearchTranscatheter aortic valve implantationCerebral embolic protectionAbsolute risk differenceAortic valve implantationRelative riskTAVI patientsValve implantationSystematic reviewCerebral embolic protection devicesMedian relative riskEmbolic protection devicesMultiple sensitivity analysesEmbolic protectionPrimary outcomeFuture trialsStandard treatmentStroke reductionBaseline riskRisk differenceElectronic databasesExpert consensusNew-generation devicesSecondary analysisStrokeRelevant reductionColchicine and high-intensity rosuvastatin in the treatment of non-critically ill patients hospitalised with COVID-19: a randomised clinical trial
Shah T, McCarthy M, Nasir I, Archer H, Ragheb E, Kluger J, Kashyap N, Paredes C, Patel P, Lu J, Kandel P, Song C, Khan M, Huang H, Haq F, Ahmad R, Howes C, Cambi B, Lancaster G, Cleman M, Dela Cruz C, Parise H, Lansky A. Colchicine and high-intensity rosuvastatin in the treatment of non-critically ill patients hospitalised with COVID-19: a randomised clinical trial. BMJ Open 2023, 13: e067910. PMID: 36828654, PMCID: PMC9971831, DOI: 10.1136/bmjopen-2022-067910.Peer-Reviewed Original ResearchConceptsStandard of careHigh-intensity rosuvastatinElectronic medical recordsCOVID-19 diseaseMedical recordsPrimary endpointThromboembolic eventsYale New Haven Health SystemSevere COVID-19 diseaseCOVID-19Prespecified primary endpointVenous thromboembolic eventsRisk of progressionCombination of colchicineSafety monitoring boardCare armHispanics/LatinosTherapeutic anticoagulationIndex hospitalisationIll patientsMedian ageFuture trialsEffect of colchicineClinical trialsMonitoring board
2008
Quantitative angiographic methods for bifurcation lesions : A consensus statement from the European Bifurcation Group
Lansky A, Tuinenburg J, Costa M, Maeng M, Koning G, Popma J, Cristea E, Gavit L, Costa R, Rares A, Van Es G, Lefevre T, Reiber H, Louvard Y, Morice M. Quantitative angiographic methods for bifurcation lesions : A consensus statement from the European Bifurcation Group. Catheterization And Cardiovascular Interventions 2008, 73: 258-266. PMID: 19085918, DOI: 10.1002/ccd.21814.Peer-Reviewed Original ResearchAngiographic Surrogate End Points in Drug-Eluting Stent Trials A Systematic Evaluation Based on Individual Patient Data From 11 Randomized, Controlled Trials
Pocock SJ, Lansky AJ, Mehran R, Popma JJ, Fahy MP, Na Y, Dangas G, Moses JW, Pucelikova T, Kandzari DE, Ellis SG, Leon MB, Stone GW. Angiographic Surrogate End Points in Drug-Eluting Stent Trials A Systematic Evaluation Based on Individual Patient Data From 11 Randomized, Controlled Trials. Journal Of The American College Of Cardiology 2008, 51: 23-32. PMID: 18174032, DOI: 10.1016/j.jacc.2007.07.084.Peer-Reviewed Original ResearchConceptsDrug-eluting stentsBare metal stentsAngiographic measuresTLR riskEnd pointDifferent drug-eluting stentsPrimary end pointRisk of TLRFollow-up angiographyLower revascularization ratesSurrogate end pointsIndividual patient dataSuitable surrogate markerDES trialsRevascularization ratesTLR rateClinical restenosisControlled TrialsFuture trialsStent implantationStent trialsSurrogate marker